Study challenges link between proton pump inhibitors and kidney disease risk

A study in Scientific Reports investigates the association between proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2RA) use on chronic kidney disease (CKD) risk.

FDA announces rare disease hub in bid to streamline treatment paths

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

July 18, 2024

FDA OKs First Pill for Postpartum Depression

The FDA approved zuranolone (Zurzuvae) as the first oral treatment for postpartum depression, the agency announced late on Friday. Until now, brexanolone (Zulresso) has been

August 6, 2023

I swore I wouldn’t become a psychiatrist

I entered medical school absolutely certain of one thing: I didn’t want to be a psychiatrist like my father. I’m sure someone like Freud could

October 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.